Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

Discover a new study that has examined the influence of clinical and histologic risk factors on long-term MASLD outcomes in ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver ...

Blood-based biomarkers offer a number of advantages over the traditional standard of fibrosis assessment of liver biopsy ... alcoholic and non-alcoholic fatty liver disease.

Background: Biopsy is the usual gold standard for liver ... alcoholic liver disease, and non-alcoholic fatty liver disease, and were validated in two independent groups including a prospective ...

SAN MATEO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Rezdiffra is currently under evaluation with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and has the potential to become the first therapy for patients ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “This will be the first AASLD Liver Meeting following the approval of Rezdiffra earlier this year, and the entire NASH community feels ...